[April 23, 2014] |
|
Research and Markets: Global Febrile Neutropenia Therapeutics Pipeline Review 2014 - Analysis of 11 Companies & 12 Drug Profiles
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/d8cp8p/febrile)
has announced the addition of the "Febrile
Neutropenia - Pipeline Review, H1 2014" report to their
offering.
This report provides comprehensive information on the therapeutic
development for Febrile Neutropenia, complete with comparative analysis
at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Febrile
Neutropenia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of
Febrile Neutropenia
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Febrile Neutropenia and enlists all their major and
minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Febrile Neutropenia products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Febrile Neutropenia pipeline on the basis of target,
MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Companies Involved in Therapeutics Development
-
Hospira, Inc.
-
Amgen Inc.
-
Eli Lilly and Company
-
Biocon Limited
-
Richter Gedeon Nyrt.
-
Sandoz International GmbH
-
Taiho Pharmaceutical Co., Ltd.
-
Sandoz Inc.
-
Xenetic Biosciences plc
-
USV Limited
-
Aequus BioPharma, Inc.
Drug Profiles
-
pegfilgrastim
-
vancomycin hydrochoride
-
(piperacillin sodium + tazobactam sodium)
-
filgrastim biosimilar
-
pegfilgrastim biosimilar
-
pegfilgrastim
-
filgrastim
-
pegfilgrastim biosimilar
-
pegfilgrastim biosimilar
-
Stimuxen
-
filgrastim biosimilar
-
pegfilgrastim biosimilar
For more information visit http://www.researchandmarkets.com/research/d8cp8p/febrile
[ Back To TMCnet.com's Homepage ]
|